KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab ; volume:13 ; number:1 ; day:29 ; month:11 ; year:2023 ; pages:1-10 ; date:12.2023
Scientific reports ; 13, Heft 1 (29.11.2023), 1-10, 12.2023
- Urheber
-
Chiari, Rita
Palladino, Silvia
Emili, Rita
Lisa, Mariagrazia De
Sarti, Donatella
Catalano, Vincenzo
Magnani, Mauro
Graziano, Francesco
Ruzzo, Annamaria
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-48304-0
- URN
-
urn:nbn:de:101:1-2024021521094269054970
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chiari, Rita
- Palladino, Silvia
- Emili, Rita
- Lisa, Mariagrazia De
- Sarti, Donatella
- Catalano, Vincenzo
- Magnani, Mauro
- Graziano, Francesco
- Ruzzo, Annamaria
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pembrolizumab
Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
Pembrolizumab for all
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
Pembrolizumab: The Nut Cracker
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
Pembrolizumab Treatment-Induced Liver Toxicity
Pembrolizumab-Induced Delayed-Onset Hepatitis
Pembrolizumab
Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
Pembrolizumab for all
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
Pembrolizumab: The Nut Cracker
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
Pembrolizumab Treatment-Induced Liver Toxicity
Pembrolizumab-Induced Delayed-Onset Hepatitis
Pembrolizumab
Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
Pembrolizumab for all
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
Pembrolizumab: The Nut Cracker
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
Pembrolizumab Treatment-Induced Liver Toxicity